# US 2018/0000821 A1 · Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0000821 A1
- Document ID: US20180000821A1
- Status: Published application
- Kind: A1
- Application number: 15/537,403
- Filed: 2015-12-18
- Published: 2018-01-04
- Earliest claimed: 2014-12-18
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: David A. CHERESH; Maricel GOZO; Mayra YEBRA; Laetitia SEGUIN
- Web page: https://patentgrep.com/patent/US20180000821A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 33/575: for cancer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In alternative embodiments, provided are compositions and methods for treating, enhancing the drug sensitivity of, and preventing the formation of cancer stems cells, including preventing or slowing the development or generation of a beta-3 (β3)-expressing, or integrin β3 (ITG-B3)-expressing cancer or tumor cells. In alternative embodiments, provided are methods using histone acetyl transferase inhibitors and/or histone methyl transferase inhibitors to determine therapeutic values in cancer cells that induce an integrin β3 (ITGB3) polypeptide expression. In alternative embodiments, provided are kits, blister packages, lidded blisters or a blister card or packet, clamshells, trays or shrink wraps, comprising at least one compound, composition or formulation used to practice a method as provided herein, and at least one Growth Factor Inhibitor.

## Claims

### Claim 1

A method for:
preventing or slowing the development or generation of a beta-3 (β3)-expressing, or integrin β3 (ITGB3)-expressing, cancer cell or tumor cell, or preventing or slowing the development of an alpha-V (α-5)/beta-3 (β3)-expressing cancer cell or tumor cell, or for preventing or slowing the phenotypic conversion of a cancer cell or tumor cell not expressing a beta-3 (β3), or integrin β3 (ITGB3), polypeptide to a cancer cell or tumor cell that expresses a beta-3 (β3), or integrin β3 (ITGB3), polypeptide, or for preventing or slowing the phenotypic conversion of a cancer cell or tumor cell not expressing an alpha-V (α-5)/beta-3 (β3) polypeptide dimer to a cancer cell or tumor cell that expresses an alpha-V (α-5)/beta-3 (β3) polypeptide dimer;
overcoming or diminishing or preventing a conversion of a cancer cell to a cancer stem cell, or acquiring a “stemness” phenotype; or, reversing, diminishing or preventing phenotypic conversion of a cancer cell to a cancer stem cell or a cancer cell having a “stemness” phenotype;
overcoming or diminishing or preventing a Growth Factor Inhibitor (GFI) resistance in a cell;
overcoming or diminishing or preventing tumor progression or metastasis of a cancer cell;
sensitizing, increasing sensitivity to or re-sensitizing a cancer stem cell, a drug resistant cancer stem cell, a tumor stem cell, or a drug resistant tumor stem cell to a cancer therapy, or making a cancer stem cell, a drug resistant cancer stem cell a tumor stem cell, or a drug resistant tumor stem cell more sensitive to a cancer therapy or making the cancer therapy more effective,
wherein optionally the cancer therapy is a drug therapy or a radiation therapy,
and optionally the drug therapy is a receptor tyrosine kinase (RTK) inhibitor therapy, or sensitizing, increasing sensitivity to or re-sensitizing a cancer stem cell or a tumor stem cell to a Receptor Tyrosine Kinase (RTK) inhibitor therapy;
sensitizing, increasing sensitivity to or re-sensitizing a dysfunctional cell, a tumor or cancer to a drug,
wherein optionally the drug is a Receptor Tyrosine Kinase (RTK) inhibitor, an EGFR1 inhibitor, an EGFR1/EGFR2 inhibitor or an IGF-1R inhibitor, or an erlotinib, a linsitinib, a lapatinib or a lenalidomide;
sensitizing, increasing sensitivity to or re-sensitizing a tumor that is resistant to a cancer or anti-tumor drug, or
reversing a tumor cell, a cancer cell, a cancer stem cell or a dysfunctional cell initiation or self-renewal capacity,
wherein optionally the cell is a tumor cell, a cancer cell, a cancer stem cell, or a dysfunctional cell,
the method comprising:
administering at least one compound, composition or formulation comprising or consisting of:
(a)
an inhibitor or depleter of an acetyl transferase gene, transcript (message) and/or an inhibitor of acetyl transferase protein expression or activity (e.g., e.g., anacardic acid, or 2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzoic acid; cyclopentylidene-[4-(4-chlorophenyl)thiazol-2-yl)hydrazone; or (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, diferuloylmethane or diferulylmethane; or (2R,3S)-rel-4-Methylene-5-oxo-2-propyltetrahydrofuran-3-carboxylic acid); or, a compound, composition or formulation that reduces or inhibits acetyl transferase gene, transcript (message) and/or protein expression or activity, or
an inhibitor of a histone acetyl transferase pathway,
wherein optionally the acetyl transferase is a histone acetyl transferase;
(b)
an inhibitor or depleter of a methyl transferase gene, transcript and/or protein expression or activity; or, a compound, composition or formulation that reduces or inhibits methyl transferase gene, transcript and/or protein expression or activity,
an inhibitor of a histone acetyl transferase pathway
wherein optionally the acetyl transferase is a histone acetyl transferase; or
(c) any combination of (a) and (b).

### Claim 2 (depends on 1)

The method of claim 1, wherein the drug therapy is a receptor tyrosine kinase (RTK) inhibitor therapy, and inhibition or depletion of acetyl transferase gene, transcript and/or protein expression or activity sensitizes, increases sensitivity to or re-sensitizes a cancer stem cell or a tumor stem cell to a Receptor Tyrosine Kinase (RTK) inhibitor therapy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the drug therapy is or comprises administration of at least one growth factor inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
(a) the at least one compound, composition or formulation, or combination of compounds, is formulated as a pharmaceutical composition;
(b) the method of (a), wherein the compound, composition or formulation or pharmaceutical composition is administered in vitro, ex vivo or in vivo, or is administered to an individual in need thereof;
(c) the method of (a) or (b), wherein the at least one compound, composition or formulation is a pharmaceutical composition is formulated for administration intravenously (IV), parenterally, nasally, topically, orally, or by liposome or targeted or vessel-targeted nanoparticle delivery;
(d) the method of any of (a) to (c), wherein the compound or composition comprises or is an inhibitor of transcription, translation or protein expression;
(e) the method of any of (a) to (d), wherein the compound or composition is a small molecule, a protein, an antibody, a monoclonal antibody, a nucleic acid, a lipid or a fat, a polysaccharide, an RNA or a DNA;
(f) the method of any of (a) to (e), wherein the compound or composition further comprises, or the method further comprises administration of: a VitaxiN™ (Applied Molecular Evolution, San Diego, Calif.) antibody, a humanized version of an LM609 monoclonal antibody, an LM609 monoclonal antibody, or any antibody that functionally blocks an αvβ3 integrin or any member of an αvβ3 integrin-comprising complex or an integrin αvβ3 (anb3)/RalB/NFkB signaling axis;
(g) the method of any of (a) to (e), wherein the compound or composition further comprises, or the method further comprises administration of, a Src inhibitor, a dasatinib, a saracatinib; a bosutinib; a NVP-BHG712, or any combination thereof; or
(h) the method of any of (a) to (g), wherein the compound or composition further comprises, or the method further comprises administration of, a Growth Factor Inhibitor, an anti-metabolite inhibitor, a gemcitabine, GEMZAR™, a mitotic poison, a paclitaxel, a taxol, Abraxane™, an erlotinib, TARCEVA™, a lapatinib, Tykerb™, or an insulin growth factor inhibitor, or any combination thereof.

### Claim 5 (depends on 1)

A kit, a blister package, a lidded blister or a blister card or packet, a clamshell, a tray or a shrink wrap, comprising:
(a) (i) at least one compound, composition or formulation used to practice the method of claim 1, and (ii); at least one Growth Factor Inhibitor,
wherein optionally the Growth Factor Inhibitor is or comprises an anti-metabolite inhibitor, a gemcitabine, GEMZAR™, a mitotic poison, a paclitaxel, a taxol, Abraxane™, an erlotinib, TARCEVA™, a lapatinib, Tykerb™, or an insulin growth factor inhibitor, or any combination thereof; or, the Growth Factor Inhibitor decreases, slows or blocks new blood vessel growth, neovascularization or angiogenesis; or, wherein administering the Growth Factor Inhibitor treats or ameliorates conditions that are responsive to blocking or slowing cell growth, and/or the development of neovascularization or new blood vessels; or
(b) the kit of (a), further comprising instructions for practicing the method of claim 1,
wherein optionally the kit, blister package, lidded blister, blister card, packet, clamshell, tray or shrink wrap comprises: an erlotinib with either Lenalidomide or PS-1145, or Lenalidomide and PS-1145.

### Claim 6 (depends on 1)

A method for determining the therapeutic value of a drug in treating a beta-3 (β3)-expressing, or integrin β3 (ITGB3)-expressing, cancer cell or tumor cell,
wherein optionally the therapeutic value comprises the property or value of whether an individual or a patient would benefit from or respond to administration of the drug, or
which individuals or patients would benefit from a combinatorial approach comprising administration of a combination of: at least one growth factor and at least one compound, composition or formulation used to practice the method of claim 1,
the method comprising:
(a) (i) administering at least one compound, composition or formulation comprising or consisting of:
an inhibitor or depleter of an acetyl transferase gene, transcript and/or protein expression or activity; or, a compound, composition or formulation that reduces or inhibits acetyl transferase gene, transcript and/or protein expression or activity,
wherein optionally the acetyl transferase is a histone acetyl transferase, or
an inhibitor or depleter of a methyl transferase gene, transcript and/or protein expression or activity; or, a compound, composition or formulation that reduces or inhibits methyl transferase gene, transcript and/or protein expression or activity,
wherein optionally the methyl transferase is a histone methyl transferase;
(ii) administering the drug whose therapeutic value is to be determined,
wherein optionally step (a)(i) is performed before step (a)(ii), or step (a)(ii) is performed before step (a)(i), step (a)(i) is performed with or about the same time as step (a)(ii); and
(b) determining the therapeutic value of the drug in treating a beta-3 (β3)-expressing, or integrin β3 (ITGB3)-expressing, cancer cell or tumor cell.

### Claim 7

(canceled)

### Claim 8

A combination, or a therapeutic combination, for:
preventing or slowing the development or generation of a beta-3 (β3)-expressing, or integrin β3 (ITGB3)-expressing, cancer cell or tumor cell, or preventing or slowing the development of an alpha-V (α-5)/beta-3 (β3)-expressing cancer cell or tumor cell, or for preventing or slowing the phenotypic conversion of a cancer cell or tumor cell not expressing a beta-3 (β3), or integrin β3 (ITGB3), polypeptide to a cancer cell or tumor cell that expresses a beta-3 (β3), or integrin β3 (ITGB3), polypeptide, or for preventing or slowing the phenotypic conversion of a cancer cell or tumor cell not expressing an alpha-V (α-5)/beta-3 (β3) polypeptide dimer to a cancer cell or tumor cell that expresses an alpha-V (α-5)/beta-3 (β3) polypeptide dimer;
overcoming or diminishing or preventing a conversion of a cancer cell to a cancer stem cell, or acquiring a “stemness” phenotype; or, reversing, diminishing or preventing phenotypic conversion of a cancer cell to a cancer stem cell or a cancer cell having a “stemness” phenotype;
overcoming or diminishing or preventing a Growth Factor Inhibitor (GFI) resistance in a cell;
overcoming or diminishing or preventing tumor progression or metastasis of a cancer cell;
sensitizing, increasing sensitivity to or re-sensitizing a cancer stem cell or a tumor stem cell to a cancer therapy, or making a cancer stem cell or a tumor stem cell more sensitive to a cancer therapy, or making the cancer therapy more effective,
wherein optionally the cancer therapy is a drug therapy or a radiation therapy,
and optionally the drug therapy is a receptor tyrosine kinase (RTK) inhibitor therapy, or sensitizing, increasing sensitivity to or re-sensitizing a cancer stem cell or a tumor stem cell to a Receptor Tyrosine Kinase (RTK) inhibitor therapy;
sensitizing, increasing sensitivity to or re-sensitizing a dysfunctional cell, a tumor or cancer to a drug,
wherein optionally the drug is a Receptor Tyrosine Kinase (RTK) inhibitor, an EGFR1 inhibitor, an EGFR1/EGFR2 inhibitor or an IGF-1R inhibitor, or an erlotinib, a linsitinib, a lapatinib or a lenalidomide;
sensitizing, increasing sensitivity to or re-sensitizing a tumor that is resistant to a cancer or anti-tumor drug, or
reversing a tumor cell, a cancer cell, a cancer stem cell or a dysfunctional cell initiation or self-renewal capacity,
wherein optionally the cell is a tumor cell, a cancer cell, a cancer stem cell, or a dysfunctional cell,
wherein the combination comprises or consists of:
(a) a compound, composition or formulation comprises or consists of:
(1) an inhibitor or depleter of an acetyl transferase gene, transcript (message) and/or protein expression or activity; or, a compound, composition or formulation that reduces or inhibits acetyl transferase gene, transcript (message) and/or protein expression or activity,
wherein optionally the acetyl transferase is a histone acetyl transferase,
(2) an inhibitor or depleter of a methyl transferase gene, transcript (message) and/or protein expression or activity; or, a compound, composition or formulation that reduces or inhibits methyl transferase gene, transcript (message) and/or protein expression or activity,
wherein optionally the methyl transferase is a histone methyl transferase, or
and combination of (1) or (2); and
(b) a growth factor inhibitor, optionally comprising a Receptor Tyrosine Kinase (RTK) inhibitor, a Src inhibitor, an anti-metabolite inhibitor, a gemcitabine, a GEMZAR™, a mitotic poison, a paclitaxel, a taxol, an Abraxane™, an erlotinib, a TARCEVA™, a lapatinib, a Tykerb™, a cetuxamib, an Erbitux™, or an insulin growth factor inhibitor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the drug therapy or the drug comprises a Receptor Tyrosine Kinase (RTK) inhibitor, a Src inhibitor, an anti-metabolite inhibitor, a gemcitabine, a GEMZAR™, a mitotic poison, a paclitaxel, a taxol, an Abraxane™, an erlotinib, a TARCEVA™, a lapatinib, a Tykerb™, a cetuxamib, an Erbitux™, or an insulin growth factor inhibitor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the drug therapy or the drug comprises an inhibitor or depleter of a Src or a Tank Binding Kinase-1 (TBK1) protein or an inhibitor of Src or TBK1 protein activation,
wherein optionally the inhibitor of the Src or the TBK1 protein activity is an amlexanox (or 2-amino-7-isopropyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid) or Aphthasol™, and (ii) an RTK inhibitor,
wherein optionally the RTK inhibitor is a Src inhibitor, an anti-metabolite inhibitor, a gemcitabine, a GEMZAR™, a mitotic poison, a paclitaxel, a taxol, an Abraxane™, an erlotinib, a TARCEVA™, a lapatinib, a Tykerb™, a cetuxamib, an Erbitux™, or an insulin growth factor inhibitor or a combination thereof.
